An advisory panel for the Food and Drug Administration concluded Wednesday that Switzerland.-based Novartis AG’s version of Amgen’s arthritis drug Enbrel should be approved, according to Reuters. The ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

(Reuters) - Novartis AG's cheaper version of Amgen Inc's blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug ...